CAFC Draws Line: First-Filed Patents Dodge ODP Bullet in Allergan-Sun Clash
Allergan's core patent on IBS-D drug eluxadoline just got a lifeline from the CAFC. In a sharp pivot from Cellect, the court says first-filed, first-issued claims with PTA can't be knocked out by later kids in the family.
theAIcatchupApr 11, 20264 min read
⚡ Key Takeaways
CAFC rules first-filed, first-issued patents with PTA immune to ODP from later-filed family claims.𝕏
Distinguishes Cellect and Gilead, focusing on filing/issuance order.𝕏
Reverses Delaware on §112 written description for Allergan continuations.𝕏
The 60-Second TL;DR
CAFC rules first-filed, first-issued patents with PTA immune to ODP from later-filed family claims.
Distinguishes Cellect and Gilead, focusing on filing/issuance order.
Reverses Delaware on §112 written description for Allergan continuations.